Prophylaxis News and Research

RSS

European Commission grants orphan drug designation for maribavir for treatment of CMV disease

ViroPharma Incorporated today announced that the European Commission has granted orphan drug designation for maribavir for treatment of cytomegaloviral disease in patients with impaired cell mediated immunity.

11 Jun 2013

Cry proteins in Bacillus thuringiensis is lethal to Anopheles gambiae, the principal mosquito vector of malaria

Researchers at The University of Texas at Dallas (UTD), led by Dr. Lee Bulla, have characterized a protein produced by the soil bacterium Bacillus thuringiensis subsp. israelensis (Bti), which is highly toxic against Anopheles gambiae, the principal mosquito vector of malaria.

6 Jun 2013

Theoretical mathematical models offer insights into therapeutic, prevention strategies for HIV

The first few hours to days following exposure to human immunodeficiency virus can be of critical importance in determining if infection occurs in a patient. But the low numbers of viruses and infected cells at this stage makes it very difficult to study these events in humans or animal models.

1 Jun 2013

Standard strategies to prevent lethal blood clots more effective than temporary placement of filters

The temporary placement of umbrella-like, metal mesh filters in abdominal veins to stop potentially lethal blood clots from traveling to the lungs during and after weight loss surgery may actually increase the risk of death in morbidly obese patients, according to new Johns Hopkins research.

30 May 2013

Australia's PBAC recommends use of XIFAXAN 550 mg for hepatic encephalopathy

Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition associated with liver disease.

24 May 2013

University of Granada researchers patent new treatment for acne

University of Granada scientists have patented a new treatment for acne that is based on completely natural substances and is much more effective than artificial formulas because it does not create resistance to bacteria and has no secondary effects.

23 May 2013

Biogen Idec announces FDA's acceptance of ELOCTATE BLA for treatment of hemophilia A

Biogen Idec announced today that the U.S. Food and Drug Administration has accepted the company's Biologics License Application for the marketing approval of ELOCTATE (recombinant factor VIII Fc fusion protein) for the treatment of hemophilia A.

13 May 2013

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.

10 May 2013

New rationale for treating patients with cirrhosis and portal hypertension

New data from clinical studies presented for the first time at the International Liver Congress- 2013 provide new rationale for an old and established treatment option for portal hypertension.

26 Apr 2013

Research shows probiotics reduce the development of hepatic encephalopathy

Probiotics could emerge as a treatment plan to manage hepatic encephalopathy (HE) therapy after a new study announced at the International Liver Congress- 2013 found they significantly reduced development of the notoriously difficult-to-treat disease.

26 Apr 2013

Perosphere, Daiichi Sankyo sign clinical trial agreement

Perosphere Inc. and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that they have entered into a clinical trial agreement under which Daiichi Sankyo will support and co-sponsor a phase 1 clinical study testing the safety, tolerability and effectiveness of PER977 to reverse the anticoagulant activity of edoxaban, Daiichi Sankyo's investigational oral, once-daily, direct factor Xa-inhibitor.

25 Apr 2013

BD receives FDA approval for second prefilled injectable drug

BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD, announced today that the U.S. Food and Drug Administration has approved the second drug to be offered in the recently launched BD Simplist line of ready-to-administer prefilled generic injectables.

From BD (Becton, Dickinson and Company) 24 Apr 2013

New assays are effective in managing patients with influenza virus infection

Over 40,000 people die each year in the United States from influenza-related diseases. In patients whose immune systems are compromised, antiviral therapy may be life-saving, but it needs to be initiated quickly. It is therefore crucial to diagnose and type the influenza rapidly.

18 Apr 2013

Study shows mathematical models can help assess effectiveness of HIV intervention combinations

South Africa is home to the largest HIV epidemic in the world with a total of 5.6 million people living with HIV. Large-scale clinical trials evaluating combination methods of prevention and treatment are often prohibitively expensive and take years to complete.

16 Apr 2013

Study: Using best-practice approach could lead to big cost reductions in hospitals nationwide

A major challenge facing today's health care community is to find ways to lower costs without compromising clinical quality. Taking that challenge to task, researchers at Medstar Health and Georgetown University School of Medicine, Washington DC, report success in using a concept called "value-based analysis," which simultaneously measures quality and cost and addresses inefficiencies in care.

11 Apr 2013

FDA accepts Merck's NDA for NOXAFIL tablets

Merck, known as MSD outside the United States and Canada, today announced that its New Drug Application for an investigational, tablet formulation of the company's antifungal agent, NOXAFIL (posaconazole), has been accepted for review by the U.S. Food and Drug Administration.

11 Apr 2013

New study suggests that Ranibizumab can be potential prophylaxis for PVR

Proliferative vitreoretinopathy, or the formation of scar tissue in the eye, is a serious, sight-threatening complication in people recovering from surgical repair of retinal detachment. PVR is difficult to predict, lacks effective treatment options, and substantially reduces an individual's quality of life.

10 Apr 2013

Research shows immune system can destroy HIV through deactivation of vif gene

Human cells have an intrinsic capacity to destroy HIV. However, the virus has evolved to contain a gene that blocks this ability. When this gene is removed from the virus, the innate human immune system destroys HIV by mutating it to the point where it can no longer survive.

29 Mar 2013

POZEN announces submission of NDA for marketing approval of PA32540/PA8140

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the marketing approval of PA32540/PA8140.

27 Mar 2013

Dialysis patients face increased risk of antibiotic-resistant infections

Patients who receive hemodialysis are at a significant risk of developing infections, a leading cause of hospitalization and death in this patient population.

13 Mar 2013